The effect of remdesivir on mortality and the outcome of patients with COVID‐19 in intensive care unit: A case–control study
Mehran Amirizadeh, Ali Kharazmkia, Kobra Sharifi Abdoli, Hadi Hayati Abbarik, Ghasem Azimi
Health Science Reports, doi:10.1002/hsr2.1676
In 2002, severe acute respiratory syndrome (SARS) first appeared in China. It quickly spread worldwide within 3 months, resulting in the first pandemic of the twenty-first century with a 10% mortality rate. 1 Several unexplained signs and symptoms of acute and chronic pulmonary pneumonia were recorded in Wuhan, China, in late
CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest.
ETHICS STATEMENT All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/ or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
TRANSPARENCY STATEMENT The lead author Ali Kharazmkia, Ghasem Azimi affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.
Mehran Amirizadeh 1 Ali Kharazmkia 1, 2 Kobra Sharifi abdoli 3 Hadi Hayati abbarik 4 Ghasem Azimi 5 1 Department of Clinical Pharmacy, School of Pharmacy,
References
Abd-Elsalam, Ahmed, Mansour, Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial, Am J Trop Med Hyg
Antinori, Cossu, Ridolfo, Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in posttreatment hospitalisation status, Pharmacol Res
Chen, Qi, Liua, Clinical progression of patients with COVID-19 in shanghai, China, J Infect
Chokkalingam, Hayden, Goldman, Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States, JAMA Network Open
Grein, Ohmagari, Shin, Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med
Gupte, Hegde, Sawant, Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database, BMC Infect Dis
Hegazy, Tharwat, Hassan, Kharazmkia, Sharifi Abdoli et al., Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients, J Clin Virol Plus
Hegazy, Tharwat, Hassan, Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients, Open Med
Jalali Farahani, Swann, Razi, Comparison of clinical, laboratory and radiological findings in Iranian elderly and Non-Elderly patients with COVID-19, J Marine Med
Lee, Santarelli, Caine, Schritter, Dietrich et al., Remdesivir for the treatment of severe COVID-19: a community hospital's experience, J Osteopath Med
Long, Xu, Xiao, Epidemiological and clinical characteristics of patients with coronavirus disease -2019 in shiyan city China, Front Cell Infect Microbiol
Mehta Pharmd, Mph, Shyh, A review of remdesivir for COVID-19: data to date, Cardiol Rev
Ohl, Miller, Lund, Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19, JAMA Network Open
Oksuz, Malhan, Gonen, Cost-Effectiveness analysis of remdesivir treatment in COVID-19 patients requiring low-flow oxygen therapy: payer perspective in Turkey, Adv Ther
Padilla, Arquiette, Mai, Singh, Galang et al., Clinical outcomes of COVID-19 patients treated with convalescent plasma or remdesivir alone and in combination at a community hospital in California's central valley, J Pharm Pharm Sci
Paranjape, Husain, Priestley, Koonjah, Watts et al., Early use of remdesivir in patients hospitalized with COVID-19 improves clinical outcomes a retrospective observational study, Infect Dis Clin Pract
Poliseno, Gallo, Cibelli, Efficacy and safety of remdesivir over two waves of the Sars-CoV-2 pandemic, Antibiotics
Rezagholizadeh, Khiali, Sarbakhsh, Entezari-Maleki, Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis, Eur J Pharmacol
Rodriguez-Guerra, Jadhav, Vittorio, Current treatment in COVID-19 disease: a rapid review, Drugs Context
Sheikhi, Mirkazehi, Azarkish, Clinical and demographic characteristics of patients with COVID -19 in iranshahr hospitals, southeastern Iran in 2020, J Marine Med. Spring
Spinner, Gottlieb, Criner, GS-US-540-5774 Investigators Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Stoeckle, Witting, Kapadia, Marks, Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir, J Med Virol
Talebi, Nematshahi, Tajabadi, Comparison of clinical and epidemiological characteristics of deceased and recovered patients with COVID -19 in Sabzevar, J Mil Med
Van Laar, De Boer, Gombert-Handoko, Guchelaar, Zwaveling, Liver and kidney function in patients with Covid-19 treated with remdesivir, Br J Clin Pharmacol
Viner, Ward, Hudson, Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents, Arch Dis Child
Walker, Siddell, Lefkowitz, Changes to virus taxonomy and the Statutes ratified by the International Committee on Taxonomy of Viruses
Wu, Peng, Huang, Genome composition and divergence of the novel coronavirus (2019-Ncov) originating in China, Cell Host Microbe
Yokoyama, Briasoulis, Takagi, Kuno, Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials, Virus Res
Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
